Ionis Pharmaceuticals (MEX:IONS) Additional Paid-In Capital : MXN59,355 Mil(As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Additional Paid-In Capital?

Ionis Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2024 (MXN55,762 Mil) to Dec. 2024 (MXN59,831 Mil) but then stayed the same from Dec. 2024 (MXN59,831 Mil) to Mar. 2025 (MXN59,355 Mil).

Ionis Pharmaceuticals's annual additional paid-in capital declined from Dec. 2022 (MXN40,159 Mil) to Dec. 2023 (MXN37,600 Mil) but then increased from Dec. 2023 (MXN37,600 Mil) to Dec. 2024 (MXN59,831 Mil).

Ionis Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Ionis Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Additional Paid-In Capital Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

37,705.66

40,292.92

40,158.84

37,599.62

59,831.08

Ionis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															37,674.28	42,197.96	55,761.79	59,831.08	59,354.60

Ionis Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Ionis Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.